Perseo Pharma

Perseo Pharma is a Swiss biotech developing next-generation enzyme replacement therapies using its proprietary nano-shield platform. The company's technology encapsulates enzymes in silica-based nanoparticles with muco-adhesive coatings, enhancing intestinal residence time and activity while remaining non-systemic. Its pipeline targets digestive enzyme deficiencies like EPI and rare metabolic disorders, with a strategic R&D collaboration with Nestlé Health Science providing validation and resources. Founded in 2019, the company is privately held and currently in the preclinical stage.

Proprietary nanotechnology platform that immobilizes enzymes on silica nanoparticles and encapsulates them in a porous organo-silica 'nano-shield.' The particles can be functionalized with muco-adhesive coatings for targeted, prolonged residence in the small intestine. The enzymes remain active but non-systemic.

Perseo competes with established makers of standard pancreatic enzyme supplements (e.g., AbbVie's Creon) and other biotechs developing next-generation formulations. Its differentiated approach of muco-adhesive, non-releasing nano-particles could provide a competitive edge in efficacy and dosing convenience if clinically proven.